ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

apatinib

Also written as “Apatinib”, “Rivoceranib” and “Apatinib Mesylate”.

Its studies are mostly in Stomach Neoplasms · Ovarian Neoplasms · Neoplasms · Carcinoma, Hepatocellular · Carcinoma, Non-Small-Cell Lung, led by 8 companies.

Drug pageApatinib: every studyMany companies study it; this page follows only the 47 they lead. All 428 studies, academic ones too, with its approvals and label.
Furthest: phase 3, since Jan 13, 201247 company-led studies, 8 open or runningNext primary completion: Dec 30, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jiangsu HengRui Medicine344 open or runningphase 3since Jan 13, 2012Aug 30, 2010none ahead
Elevar Therapeuticsits history only70 open or runningphase 3since Jan 24, 2017Dec 18, 2011none ahead
Bukwang Pharmaceuticalits history only10 open or runningphase 1since Feb 26, 2016Feb 26, 2016none ahead
GrandPharma (China)its history only11 open or runningphase 2since Aug 13, 2025Aug 13, 2025Dec 30, 2027phase 2 · NCT07334483
Guangzhou Virotech Pharmaceuticalits history only11 open or runningphase 3since May 8, 2026May 8, 2026Dec 31, 2028phase 3 · NCT07589244
Hansoh Pharmaceutical Groupits history only11 open or runningphase 1since Jan 7, 2025Jan 7, 2025none ahead
HRYZ Biotechits history only11 open or runningearly phase 1since Aug 26, 2019Aug 26, 2019none ahead
Qilu Pharmaceuticalits history only10 open or runningphase 2since Aug 14, 2017Aug 14, 2017none ahead

Also a collaborator on its studies: Bukwang Pharmaceutical.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Jiangsu HengRui Medicine only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 18 studies since Aug 30, 2010.

  1. Dec 13, 2019Phase 3 study in PD-L1 Positive Non-small Cell Lung CancerNCT04203485 · 762 enrolled
  2. Jan 12, 2020Phase 3 study in Ovarian NeoplasmsNCT04229615 · 690 enrolled · China
  3. Mar 3, 20202 phase 3 studiesNCT04296370, NCT04335006
  4. Mar 17, 2020Phase 1 study in Advanced Solid TumorNCT04322552 · 18 enrolled · China
  5. Apr 8, 2020Phase 1 study in Healthy SubjectsNCT04341090 · 42 enrolled · China
  6. Apr 9, 2020Phase 3 study in Stomach NeoplasmsNCT04342910 · 550 planned · China
  7. May 6, 2020Phase 2 study in Ovarian NeoplasmsNCT04383977 · 54 enrolled
  8. May 13, 2020Phase 1 study in NSCLCNCT04390984 · 22 enrolled · China
  9. Jun 1, 20202 phase 1 studiesNCT04414852, NCT04457180
  10. Aug 16, 2020Phase 2 study in Ovarian NeoplasmsNCT04517357 · 100 enrolled · China
  11. Nov 19, 2020Phase 3 study in Carcinoma, HepatocellularNCT04639180 · 687 enrolled · China
  12. Apr 26, 2021Phase 2 study in Metastatic Castration Resistant Prostate CancerNCT04869488 · 93 enrolled · China
  13. Jul 15, 2021Phase 3 study in Advanced Hepatocellular Carcinoma (HCC)NCT04985136 · 1 enrolled · China
  14. Apr 2, 2022Phase 3 study in Carcinoma, HepatocellularNCT05320692 · 423 enrolled · China

TargetBeta

KDR →read by rule
“Vascular endothelial growth factor receptor 2 inhibitor”ChEMBL 37, by rule

Other programs on KDR

ProgramCompanyFurthest phaseStudies
lenvatinibruleEisaiphase 481
nintedanibruleBoehringer Ingelheimphase 476
regorafenibruleBayerphase 440
cabozantinibruleExelixisphase 436
RamucirumabruleEli Lillyphase 358
AxitinibrulePfizerphase 345
anlotinibruleSino Biopharmaceuticalphase 340
vorolanibruleBetta Pharmaceuticalsphase 324
zanzalintinibruleExelixisphase 317
chiauranibruleChipscreen Biosciencesphase 315
Aurora B/VEGFR/FGFR Inhibitor AL8326ruleadvenchen-laboratories-nanjing-ltdphase 38
AXL/FLT3/VEGFR2 Inhibitor KC1036rulebeijing-konruns-pharmaceutical-co-ltdphase 37

Studies

All 34 Jiangsu HengRui Medicine leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05320692Carcinoma, Hepatocellular · China3Active, not recruitingJul 30, 2026423
NCT04985136Advanced Hepatocellular Carcinoma (HCC) · China3TerminatedDec 29, 20211
NCT04869488Metastatic Castration Resistant Prostate Cancer · China2CompletedFeb 14, 202393
NCT04639180Carcinoma, Hepatocellular · China3Active, not recruitingJul 31, 2026687
NCT04517357Ovarian Neoplasms · China2CompletedNov 30, 2023100
NCT04457180Advanced Solid Tumor · China1CompletedMay 20, 202118
NCT04414852Subjects With Impaired Renal Function and Healthy Subjects1UNKNOWNJan 15, 202124
NCT04390984NSCLC · China1UNKNOWNFeb 202122
NCT04383977Ovarian Neoplasms2UNKNOWNDec 202054
NCT04342910Stomach Neoplasms · China3RecruitingApr 1, 2026550
NCT04341090Healthy Subjects · China1CompletedJul 6, 202042
NCT04335006Breast Neoplasms · China3TerminatedApr 14, 202380
NCT04322552Advanced Solid Tumor · China1CompletedApr 3, 202118
NCT04296370Treatment in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation · China3RecruitingJun 30, 2022474
NCT04229615Ovarian Neoplasms · China3UNKNOWNJun 30, 2023690
NCT04203485PD-L1 Positive Non-small Cell Lung Cancer3UNKNOWNMar 31, 2022762
NCT04000295Ovarian Neoplasms · China3UNKNOWNJan 2021280
NCT03945604Triple Negative Breast Neoplasms · China1CompletedFeb 9, 202132
NCT03711279Sarcoma · China2TerminatedJun 21, 202199
NCT03491631Neoplasms · China1UNKNOWNJun 202323
NCT03472365Stomach Neoplasms · China2CompletedNov 25, 202067
NCT03463876Carcinoma, Hepatocellular · China2CompletedMar 10, 2021190
NCT03245307Cytochrome P450 Interaction · China1UNKNOWNApr 30, 201820
NCT03075462Ovarian Neoplasms · China1CompletedAug 22, 202198
NCT03026881Recurrence · China1UNKNOWNApr 201824
NCT02836171Neoplasms · China1CompletedFeb 201720
NCT02836821Neoplasms · China1CompletedFeb 201720
NCT02764268Stomach Neoplasms · China–CompletedDec 10, 201860
NCT02332512Carcinoma, Non-Small-Cell Lung · China3UNKNOWNAug 2017417
NCT02329860Carcinoma, Hepatocellular · China3CompletedDec 15, 2017400
NCT01531777Colorectal Neoplasms · China2CompletedNov 201440
NCT01512745Stomach Neoplasms · China3CompletedMay 2013267
NCT01270386Carcinoma, Non-Small-Cell Lung · China2CompletedJul 2011136
NCT01192971Neoplasms · China2CompletedJul 2013121

How it is read

Names in the registry

  • “Apatinib”, 13 entries
  • “Rivoceranib”, 5 entries
  • “Apatinib Mesylate”, 5 entries
  • “apatinib”, 3 entries
  • “Fluzoparib+Apatinib”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.